TY  - JOUR
AU  - Miglis, Mitchell G
AU  - Adler, Charles H
AU  - Antelmi, Elena
AU  - Arnaldi, Dario
AU  - Baldelli, Luca
AU  - Boeve, Bradley F
AU  - Cesari, Matteo
AU  - Dall'Antonia, Irene
AU  - Diederich, Nico J
AU  - Doppler, Kathrin
AU  - Dušek, Petr
AU  - Ferri, Raffaele
AU  - Gagnon, Jean-François
AU  - Gan-Or, Ziv
AU  - Hermann, Wiebke
AU  - Högl, Birgit
AU  - Hu, Michele T
AU  - Iranzo, Alex
AU  - Janzen, Annette
AU  - Kuzkina, Anastasia
AU  - Lee, Jee-Young
AU  - Leenders, Klaus L
AU  - Lewis, Simon J G
AU  - Liguori, Claudio
AU  - Liu, Jun
AU  - Lo, Christine
AU  - Ehgoetz Martens, Kaylena A
AU  - Nepozitek, Jiri
AU  - Plazzi, Giuseppe
AU  - Provini, Federica
AU  - Puligheddu, Monica
AU  - Rolinski, Michal
AU  - Rusz, Jan
AU  - Stefani, Ambra
AU  - Summers, Rebekah L S
AU  - Yoo, Dallah
AU  - Zitser, Jennifer
AU  - Oertel, Wolfgang H
TI  - Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder
JO  - The lancet  / Neurology
VL  - 20
IS  - 8
SN  - 1474-4422
CY  - London
PB  - Lancet Publ. Group
M1  - DZNE-2022-00138
SP  - 671 - 684
PY  - 2021
AB  - Patients with isolated rapid-eye-movement sleep behaviour disorder (RBD) are commonly regarded as being in the early stages of a progressive neurodegenerative disease involving α-synuclein pathology, such as Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. Abnormal α-synuclein deposition occurs early in the neurodegenerative process across the central and peripheral nervous systems and might precede the appearance of motor symptoms and cognitive decline by several decades. These findings provide the rationale to develop reliable biomarkers that can better predict conversion to clinically manifest α-synucleinopathies. In addition, biomarkers of disease progression will be essential to monitor treatment response once disease-modifying therapies become available, and biomarkers of disease subtype will be essential to enable prediction of which subtype of α-synucleinopathy patients with isolated RBD might develop.
KW  - Biomarkers
KW  - Disease Progression
KW  - Humans
KW  - Prognosis
KW  - REM Sleep Behavior Disorder: complications
KW  - REM Sleep Behavior Disorder: diagnosis
KW  - Synucleinopathies: diagnosis
KW  - Synucleinopathies: etiology
KW  - alpha-Synuclein
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC8600613
C6  - pmid:34302789
DO  - DOI:10.1016/S1474-4422(21)00176-9
UR  - https://pub.dzne.de/record/163375
ER  -